Literature DB >> 21657957

Inhibition of histone deacetylase 6 as a therapeutic strategy for acute lymphocytic leukemia.

Elizabeth A Eklund1, Leonidas C Platanias.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21657957     DOI： 10.3109/10428194.2011.577259

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  4 in total

1.  Selective inhibition of histone deacetylase 6 alters the composition of circulating blood cells in a lethal septic model.

Authors:  Ting Zhao; Yongqing Li; Baoling Liu; Ihab Halaweish; Ralph Mazitschek; Hasan B Alam
Journal:  J Surg Res       Date:  2014-02-04       Impact factor: 2.192

2.  Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors.

Authors:  Priya Poonia; Monika Sharma; Prakash Jha; Madhu Chopra
Journal:  Mol Divers       Date:  2022-10-10       Impact factor: 3.364

3.  Inhibition of histone deacetylase 6 restores innate immune cells in the bone marrow in a lethal septic model.

Authors:  Ting Zhao; Yongqing Li; Baoling Liu; Baihong Pan; Xin Cheng; Patrick Georgoff; Hasan B Alam
Journal:  J Trauma Acute Care Surg       Date:  2016-01       Impact factor: 3.313

4.  The Role of HDACs as Leukemia Therapy Targets using HDI.

Authors:  Ahmad Ahmadzadeh; Elahe Khodadi; Mohammad Shahjahani; Jessika Bertacchini; Tina Vosoughi; Najmaldin Saki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-10-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.